Genetic related clinical trials are available through the Warren Cancer Research Foundation. The Foundation administers nationally recognized clinical trials for cardiology, cancer and genetic related conditions.
Choosing to take part in a clinical trial is a decision that only you, those close to you and your medical providers can make. Patients should understand the possible benefits as well as drawbacks. Your physician, nurses and members of the research team can help you find answers to any questions you may have including:
- possible side effects;
- what, if any, other options are available; and
- costs and insurance coverage of the study.
There are many questions you may have about clinical research and if it's right for you. The staff at Warren Cancer Research Foundation
is here to help. They work with some of the best research investigators/physicians in their fields of expertise to make clinical trial participation a possibility for residents of Oklahoma and surrounding states.
For more information on how to access clinical trials available in the area, please ask your physician or call 918-491-5878.
Warren Cancer Research Foundation
6465 South Yale Avenue, Suite 707
Tulsa, OK 74136
Available Genetic Related Clinical Trials
Study Title: Signature Genomic Laboratories (SGL) Cancer Microarray Feasibility Study
Study Status: Open
The advances in technology that have resulted from research efforts now make it possible for scientists to acquire a much better understanding of the causes of cancer, how various cancers differ, and how those differences affect the response to treatment. Microarray analysis plays an important part in cancer research. A Microarray is a glass slide on which sequences of DNA are fixed in an orderly arrangement. The microarray is used for surveys of many genes simultaneously as the sequences contained on a single microarray can number in thousands. Recently, Signature Genomic Laboratory developed and completed early testing of the Signature OncoChipTM microarray.
Patients will be asked to take part in this study because they have been diagnosed with cancer or have a suspected diagnosis of cancer and we would like to obtain sufficient residual DNA for research purposes related to the Signature OncoChipTM microarray.
Nationally about 500 patients will take part in this study. Locally, approximately 20 patients are expected to participate.
Study Title: LSD Registry Program (Pompe, MPS I, Fabry, & Gaucher)
Study Status: Open
The Lysosomal Stoarge Diseases (LSD) Registry Program (including but not limited to, Gaucher, Fabry, MPS I and Pompe Diseases) is a longitudinal, international, observational database that tracks outcomes of routine clinical practice for patients with these LSD diseases. Not all patients in the Registry are on enzyme replacement therapy (ERT).
Data collected from physicians will represent LSD disease practice patterns under common clinical conditions. Thus, the data collected by this international, collaborative Registry will provide information to better characterize the natural history and progression of these LSD diseases, as well as the clinical responses of patients whose physicians have prescribed ERT when ERT is available.
Nationally, the total number of people who will participate in the LSD Registry is difficult to predict as not all patients have been identified. Locally, approximately 12 patients are expected to participate.
Study Title: Region 4 Long Term Follow Up and Clinical Outcomes: Inborn Errors of Metabolism Registry
Study Status: Open
Patients are asked to participate in this registry if they have a diagnosis of one of the metabolic disorders that the study doctor is studying. Most metabolic problems are rare, and individual research centers do not see enough patients to study and publish new information about these conditions. By grouping together, the researchers in this region (Illinois, Indiana, Kentucky, Michigan, Minnesota, Ohio, Wisconsin and Oklahoma) hope to answer questions about treatment and outcomes.
Nationally about 1,000 patients will take part in this study. Locally, approximately 25 patients are expected to participate.
Study Title: Alglucosidase Alfa Temporary Access Program (AATAP)
Study Status: Closed
AATAP is a clinical research program for patients with Pompe disease (GAA deficiency).
The purpose of this research program was to provide eligible subjects in the United States with Pompe disease a way to access investigational alglucosidase alfa manufactured at large production scales for a limited time until this product, known as Lumizymetm (alglucosidase alfa), is approved for commercial use by the Food and Drug Administration (FDA) and sufficient commercial supply is available.
As done with other Genzyme enzyme replacement therapies, the manufacturing process for alglucosidase alfa was developed at a smaller volume and subsequently scaled-up to produce larger volumes in order to make enough product to continue to treat patients with Pompe disease. Lumizyme was approved by the US Food and Drug Administration on May 24, 2010; therefore, enrollment in this study has been closed.
A total of 184 patients were enrolled in the study nationally. Locally, 2 subjects were enrolled.
Study Title: Natural History of Metabolic Disorders Identified by Newborn Bloodspot Screening
Study Status: Pending
Information to be added once study is open to accrual.